Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch
This article was originally published in The Tan Sheet
Executive Summary
The degree of difficulty is tremendous for the first novel switch FDA approves, but it would provide a template others can follow. FDA’s interest in fostering innovative OTC switches could work in favor of proposals to make currently Rx ingredients indicated for a chronic condition available nonprescription.
You may also be interested in...
US FDA Advisory Committee Members Say Votes Should More Directly Affect Agency Decisions
Survey of advisory committee members finds many believe an overwhelmingly negative vote should prevent a product approval. Survey was prompted by FDA accelerated approval of Alzheimer’s disease treatment Aduhelm despite overwhelming committee rejection.
Room For Innovative Switches Could Lurk In Existing FDA Framework
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
MacuHealth Asserts ‘Rigorous Process’ In Research Supporting Claims, But No Bill Of Health From NAD
“MacuHealth believes challenged claims are thoroughly supported by the multitude of peer reviewed, published scientific studies” but NAD review on Vision Elements challenge finds firm’s research doesn’t support its claims.